Observations on the expression of human papillomavirus major capsid protein in HeLa cells by unknown
Xiao et al. Cancer Cell International  (2015) 15:53 
DOI 10.1186/s12935-015-0206-0PRIMARY RESEARCH Open AccessObservations on the expression of human
papillomavirus major capsid protein in
HeLa cells
Chang-Yi Xiao1*, Bing-Bing Fu1, Zhi-Ying Li2, Gohar Mushtaq3, Mohammad Amjad Kamal4,5, Jia-Hua Li1,
Gui-Cheng Tang1 and Shuo-Shuang Xiao1Abstract
Background: The goal of this study was to identify the nature of the inclusion bodies that have been found in
HeLa cells (cervical cancer immortal cell line) by electron microscope and to determine whether the major capsid
protein (L1) of human papillomavirus (HPV) can be expressed in HPV-positive uterine cervix cancer cells.
Methods: HPV L1 protein expression in HeLa cells was detected with anti-HPV L1 multivalent mice monoclonal
antibody and rabbit polyclonal anti-HPV L1 antibody by ELISA, light microscope immunohistochemistry, electron
microscope immunocytochemistry and Western blotting assays. Reverse transcriptional PCR (RT-PCR) was performed
to detect the transcription of L1 mRNA in HeLa cells. The immortalized human keratinocyte HeCat was used as the
negative control.
Results: HPV L1 proteins reacted positively in the lysate of HeLa cells by ELISA assays. HRP labeled light microscope
immunohistochemistry assay showed that there was a strong HPV L1 positive reaction in HeLa cells. Under the
electron microscope, irregular shaped inclusion bodies, assembled by many small and uniform granules, had been
observed in the cytoplasm of some HeLa cells. These granules could be labeled by the colloidal gold carried by
HPV L1 antibody. The Western blotting assay showed that there was a L1 reaction strap at 80–85 kDa in the HeLa
cell lysates, hence demonstrating the existence of HPV18 L1 in HeLa cells. RT-PCR assay showed that the L1 mRNA
was transcribed in HeLa cells.
Conclusions: The inclusion bodies found in the cytoplasm of HeLa cells are composed of HPV18 L1 protein.
Since HeLa cell line is a type of cervical cancer cells, this implies that HeLa cells have the ability to express HPV L1
proteins.
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Human papillomavirus major capsid protein (HPV L1) is
the main protein constituent of the HPV particle coat.
The HPV particle coat is highly immunogenic and it can
effectively stimulate the humoral immunity and cellular
immunity of human body, thus preventing the body from
being re-infected by the same HPV [1–4]. This is the main
reason why the L1 protein is used as HPV prophylactic
vaccine [5,6]. However, so far no noticeable progress has* Correspondence: xiaochy@ctgu.edu.cn
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vaccine to treat tumors caused by HPV or using it as the
target protein for biotherapy of tumors caused by HPV
due to the lack of expression of HPV L1 in tumor cells.
Most researchers think that HPV does not cause any L1
protein expression in tumors [7,8]. The L1 expression is
dependent on cell differentiation [9–13] but owning to the
dedifferentiation of tumor cells, the expression program of
the L1 gene cannot be activated even if tumor cells have
intact episomal HPV genomes. Hence, there is no L1 pro-
tein expression [9–13]. Furthermore, some genes in the
virus genome are lost and HPV genes are rearranged when
HPV genome is integrated into the nucleotide sequence ofle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Electropherogram of RT-PCR products. After reverse transcription
of mRNA extracted from HeLa cells and HaCat cells, the mRNA were
amplified by MY09/11 primer and the products were electrophoresed
in sepharose gel. Lane 3 is DNA Marker, from top to bottom are 2000,
1000, 750, 500, 250 and 100 bp. Lane 1 is the amplification products
lane of cDNA in HeLa cells. The HPV L1 transcription product strip at
450 bp shows that there is L1 genetic expression in HeLa cells. Lane 2
is the GAPDH internal control lane in HeLa cells and its strip is present
at 258 bp. Lane 4 is the GAPDH internal control lane in HaCat cells and
its strip is present at 258 bp. Lane 5 is the MY09/11 universal primer
amplification compared lane in HaCat cells and there is no amplified
strip in this lane
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gene is intact in the integrated HPV genome, the startup
sequence needed for L1 normal transcription undergoes
rearrangement from upstream to downstream of L1 gene.
Consequently, the transcription of the L1 gene cannot
start, thus there is no L1 expression [11–16]. Based on the
above-mentioned reasons, it is widely believed by re-
searchers in the field of HPV-associated tumors that there
is no L1 protein expression in HPV induced tumors
[9–13,16]. But the question arises as to whether the above
viewpoint really true? The answer to this question may be
“no” based on our observation of the HeLa cells.
The HeLa cell line was derived from a case of adenocar-
cinoma of the uterine cervix in 1952 and it was estab-
lished to be the first human cervical epithelium
carcinoma cell line with a long term cell culture [17].
The existence of HPV18 DNA in HeLa cell line was con-
firmed after its identification in a case of cervical cancer
viable tissue in 1984. There are two HPV18 DNA ge-
nomes in HeLa cell. The length of these two HPV18
DNA genomes is 7.8 kb and 6.9 kb, respectively, after
Ecor RI analysis, and there is 900 bp deficiency in the
latter [18]. As a representative HPV18 positive human
cervix cancer cell line, the HeLa cell is used widely in all
kinds of cervix cancer researches and it plays an import-
ant role in the research of cervix cancer cell biology and
the diagnosis and treatment of cervix cancer. Is there
HPV L1 expression in HeLa cell? To the best of our
knowledge, no previously reported study on HeLa cells
has ever reported HPV L1 expression in HeLa cells
[14,17–20]. However, we are reporting in our present re-
search the presence of inclusion bodies of different
amount, sizes and shapes in the HeLa cell cytoplasm as
seen under the electron microscope. This goal of our re-
search is to identify whether this kind of material is the
L1 protein expressed by HPV18 genome.
Results
Results of HPV L1 assay by ELISA
Extracted from HeLa cells, the protein was detected
using HPV L1 mice antibody to show HPV L1 protein
expression. The HaCat cells served as negative control.
The results revealed that the OD value of HeLa cells
was 0.9056 ± 0.2650 while the OD value of HaCat cells
was 0.1694 ± 0.0615, hence showing a significant differ-
ence (P < 0.01).
Results of RT-PCR
The cultured HeLa cells synthetized cDNA by reverse
transcription and amplification reaction. GAPDH internal
control products presented a strap at 258 bp when PCR
products were in agarose gel electrophoresis, which shows
that mRNA extraction and the subsequent operations were
performed well. The products produced by synthetizedcDNA amplified by MY09/11 universal primer presented a
strap at 450 bp after electrophoresis. This strap is produced
by the amplification products after HPV L1 universal pri-
mer amplification. It indicates the presence of L1 genetic
transcription products which come from L1 mRNA pro-
duced in the HeLa cells (Fig. 1).L1 protein expression assay by light microscope
immunocytochemistry
Results of the immunocytochemistry assay for cultured
HeLa cells using mice anti-HPV L1 multivalence mono-
clonal antibody show that HeLa cells in positive reaction
which manifests as yellow color all over the whole HeLa
cell. The reaction of cytoplasm is stronger and it is of
darker stain (Fig. 2a). This result demonstrates the exist-
ence of HPV L1 protein in HeLa cells. There is no posi-
tive stain reaction in HaCat cells used as negative
control after the same assay, which is in sharp contrast
to the positive reaction in HeLa cells (Fig. 2b).
Fig. 2 HPV L1 immunocytochemistry assay. a HeLa cells. There were positive reactions which were yellow in cytoplasm and nucleus in HeLa cells
detected using anti-HPV L1 monoclonal antibody and the stain in cytoplasm is darker. The reaction shows the existence of HPV L1 in HeLa cells.
b HaCat cells. No positive reaction was detected in HaCat cells using anti-HPV L1 monoclonal antibody
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Clumped inclusion bodies have been observed in cytoplasm
analogue of partial HeLa cells under electron microscope at
lower power. These clumped inclusion bodies with different
sizes and shapes are not in other cells. The contents of
assemble bodies in cells also vary from each other. Some
cells have a large number of clumped cytorryctes while
some have barely any clumped inclusion bodies. The clus-
tered content is not obviously associated with any cell activ-
ity, that is, there is no evident relationship between the
clumped content with the growth rate of the cells, whether
the cell is in active growth or in apoptosis. At high magnifi-
cation, it can be seen that these clumpings are not wrapped
up by surrounding membranes but rather there are clear
dividing lines between the clumped inclusion bodies and
other components in the cytoplasm. These clumped inclu-
sion bodies are densely assembled by plenty of round gran-
ules that are tiny, with diameter of about 25–30 nm and
uniform size, seen scattered in the cytoplasm and nucleus.
No inclusion bodies have been observed in the cell nucleus
(Figs. 3, 4, 5, 6 and 7).
The HeLa cell ultrathin section was reacted with mice
anti-HPV L1 multivalence antibody and then combined
with colloidal gold labeled goat anti-mice second
antibody. The resulting sample after colloidal goldimmunocytochemistry reaction shows the existence of
dense gold particles in inclusion bodies zone in the
HeLa cell. Large numbers of inclusion body granules ap-
pear labeled by colloidal gold particles. However, almost
no gold particles are observed in the zone without inclu-
sion body granules. The difference is evident. The scat-
tered granules can be labeled by the colloidal gold. This
reaction demonstrates that these granules can sign the
specificity of HPV L1 antibody with colloidal gold, which
implies that these granules may be HPV L1 protein or
fusion protein containing L1 (Fig. 8).
HPV L1 protein expression assay by Western blotting
The results of this assay showed that there were puce
colored positive stripes appearing near 55 kDa when re-
combinant HPV18 L1 protein was reacted with rabbit
broad spectrum anti-HPV L1 polyclonal antibody and
mice anti-HPV L1 multivalence monoclonal antibody,
respectively. However, for the HeLa cell lysates, the posi-
tive stripes appeared at 80–85 kDa when reacted with
these two types of antibodies. There was no stripe in im-
mortalized keratinocyte – the HaCat cell which is the
negative control. This demonstrates that there is HPV
L1 protein expression in HeLa cells, despite the possibil-
ity that it may not be pure L1 protein but a kind of fu-
sion protein containing HPV L1 (Fig. 9).
Fig. 3 HeLa cell electron micrograph. In the graph, there is a HeLa cell in apoptosis. Many clumped inclusion bodies can be seen in the HeLa cell
cytoplasm (indicated by the arrow). These clumped bodies appear in different sizes and shapes. No inclusion bodies are seen in the cell nucleus
Xiao et al. Cancer Cell International  (2015) 15:53 Page 4 of 9Discussion
It is generally acknowledged that HPV L1 protein ex-
pression is associated with the maturation process from
basal cells to superficial epithelial cells. Complete life
cycle of HPV with whole virus genome only appears in
the differentiating keratinocyte [9,11–13,21]. Thus, HPV
L1 can only be expressed in the superface cells of squa-
mous epithelium and can be highly expressed in low-
grade cervix epithelium diseases. In high-grade diseases,
virus DNA integrates to the host DNA and the upstream
regulation sequence of HPV L1 gene is lost because of the
rearrangement of virus genome, which suppresses the L1
gene transcription. This results in halted production of L1
mRNA, which means that the L1 protein cannot beFig. 4 The graph of partial enlargement of the HeLa cell electron microgra
At higher magnification, these inclusion bodies can be seen as dense aggrexpressed [11–13,15,16]. Moreover, it is widely considered
that L1 protein is dependent on cell differentiation, and
even though the tumor cells have intact HPV episomes,
the L1 gene expression program is unable to start because
of the dedifferentiation of the tumor cells, which results in
no expression of L1 protein. However, it is not clear as to
whether this viewpoint is applicable to adenocarcinomas
infected by viruses including HPV18, or 45.
Previous studies have indicated that is the possibility of
L1 expression in the tissue cells of tumors caused by
HPV is not only connected to the differentiation state of
the tumor tissue but also related to the host genome
position integrated by HPV virus genome [22–24]. Al-
though HPV18 virus genome is likely to lose partialph in Fig. 3. Two of the inclusion body structures are highly magnified.
egations of plenty of tiny granules with uniform diameter
Fig. 5 HeLa cell electron micrograph. There is an active HeLa cell. Many clumped inclusion bodies can be seen in the cytoplasm of the HeLa cells
(indicated by the arrow). These clumped bodies appear in different sizes and shapes. No inclusion bodies are seen in the cell nucleus
Xiao et al. Cancer Cell International  (2015) 15:53 Page 5 of 9genome when it is integrating, several studies have re-
vealed that the loss of L1 genome is minimal, hence
keeping it complete [17,18,25]. It is well-known that two
integrated HPV18 virus genomes exist in the HeLa cell,
and they are 7.8 kb and 6.9 kb respectively [18]. Because
there is a 3’ splice site at the beginning of the remaining
HPV L1 gene and a late polyA signal behind the gene
[26,27], when the inserted site of the HPV18 genome is
right in the transcription sequence of host genome and
in a suitable internal environment of cells, the HPV18
L1 is likely to be transcribed and spliced appropriately to
express L1 protein. Some researchers have discovered
the existence of HPV transcript derived from host
chromosome and also transcript of L1 when theyFig. 6 The graph of partial enlargement of the HeLa cell electron microgra
At higher magnification, this inclusion body can be seen as a dense aggreganalyzed the HPV genetic transcripts in HPV integrated
tumor tissue [22,23]. The research reported in this paper
utilized RT-PCR to detect the existence of HPV L1 tran-
script in HeLa cells. Our results demonstrated that the
L1 genetic transcription of HPV genome integrated in
HeLa cells can be detected.
When HeLa cells were observed under electron micro-
scope, some inclusion bodies were found with different
numbers, sizes and shapes in the cells cytoplasm. This
research elucidated the nature of these materials. ELISA,
immunocytochemistry, electron microscope immuno-
cytochemistry and Western blotting were used to dem-
onstrate that there is HPV L1 expression in HeLa cells
and that the HPV L1 exists as granules with same sizeph in Fig. 5. Two of the inclusion body structures are highly magnified.
ation of plenty of tiny granules with uniform diameter
Fig. 7 The graph of partial enlargement of the HeLa cell electron micrograph in Fig. 6. Observed at high magnification, these inclusion bodies
can be seen as dense aggregations of plenty of round granules with uniform diameter of about 30 nm
Xiao et al. Cancer Cell International  (2015) 15:53 Page 6 of 9which form the inclusion bodies in the cytoplasm of
HeLa cells. These inclusion bodies are composed of
large number of tiny granules with similar shapes, uni-
form diameter about 25–35 nm and bigger electron
density. These granules can bind to anti-HPV L1 anti-
body and be labeled by secondary antibody with col-
loidal gold. Although they are composed by HPV L1, it
is difficult to figure out morphologically what material
constitutes these granules. Previous researches have
shown that formed L1 protein monomers can assemble
to pentamer capsomeres automatically and further form
into whole viral shells or full-size virus-like particles
(VLP) about 55 nm in diameter, all comprising of 72Fig. 8 HeLa cell electron microscopy immunocytochemistry stain graph. H
antibody immunocytochemistry reaction. It can be seen that there are den
inclusion bodies while there are barely any gold particles in the surroundin
bodies are HPV 18 L1 or the fusion protein containing HPV18 L1pentamer capsomeres [28]. When 10 amino acid resi-
dues are truncated in the beginning of L1 N-terminal,
the pentamers may only assemble to small VLP about
30 nm in diameter which is composed of 12 pentamers
[28,29]. However, when there is much loss of amino acid
residue in the L1 C-terminal sequence, the pentamer
capsomeres fail to assemble into viral shell or VLP
[28,29]. In this research, sophisticated structure of the
granules labeled by colloidal gold under the electron
microscope is barely visible owning to the quality of
the microscope filmmaking, but it can be determined
that its diameter is about 25–35 nm. In this research,
Western blotting detection shows that the positiveeLa cells were labeled using colloidal gold after HPV L1 specific
se gold particles in the compact zone of granules which form the
g cytoplasm. This shows that the granules composing the inclusion
Fig. 9 HPV L1 protein expression detection in HeLa cells by Western blotting. Lane 4 is Maker, the molecular weight of which are respectively
55, 72(red), 95, 130 kDa. Lanes 1 to 3 are the results of rabbit anti-HPV L1 broad spectrum polyclonal antibody reaction. Lanes 5 to 7 show the
results of mice anti-HPV L1 multivalence monoclonal antibody reaction. Lane 1 and 7 are HPV18 L1 recombinant protein. Lane 2 and 6 are HaCat
cell lysates. Lane 3 and 5 are HeLa cell lysates
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tween 80–85 kDa, which is remarkably higher than the
normal site of L1 at 56 kDa. This indicates that the
expressed L1 protein in HeLa cells is more likely to be a
kind of fusion protein. Further research is needed to deter-
mine the exact type of protein that is fused with HPV L1.
Clinical research has shown that the HPV L1 protein ex-
presses in the tumor cells. Researchers such as Lee [30]
performed HPV L1 detection for 102 cervix cancer pa-
tients and found that HPV L1 protein can be expressed in
cervix cancer with 40 % expression rate as well as low
grade squamous intraepithelial lesions and high grade
squamous intraepithelial lesions (expression rate is about
75.8 and 40 %, respectively). Our research team has con-
ducted investigation to determine HPV L1 expression in
cervix tissue. We have found that there is HPV L1 expres-
sion in tumor tissue, and HPV L1 expression in some tis-
sues is related to the differentiation of the tumor tissue
[24]. These researches demonstrate that HPV L1 expres-
sion in tumor tissue or tumor cells is not a rare event.
The results of this present research may be entirely dif-
ferent from mainstream view formed in this research
field, but based on research studies and clinical reports,
we assume that HPV L1 can be expressed in certain cervix
cancer tissues or cells. This expression is highly related to
the physical status of virus genome in the tumor tissue or
cells (integrated or episomal forms), the differentiation of
tumor tissue (high differentiation or low differentiation)
and the nature of host genome sequence inserted into by
virus genome (can encode or not). We also observed that
granules exist not in all HeLa cells. Some cells have lots of
granules while some cells have few, hence, there is no def-
inite relationship between the amount of granules and the
state of cells (active or in apoptosis). The precise mechan-
ism of L1 expression in HeLa cells is the subject of further
research in the future.The research presented in this paper has two aspects
of significance. First, because HPV L1 protein expressed
in tumor cells is highly immunogenic, the L1 protein
can be used as a target protein for tumor biotherapy.
When the present HPV L1 VLP vaccine is used as
prophylactic vaccine, it can play a crucial role as the
therapeutic vaccine to tumors with L1 protein expres-
sion of corresponding type as well. Next, if there is L1
expressed in tumor cells, L1 can work as tumor antigen
and it is beneficial for body's immune system to recognize
and remove these tumors. It is also possible that cancer
patients with L1 expression may be able get better prog-
nosis than those with no L1 expression [31].
Methods
Reagents
HeLa cells and immortalization keratinocytes HaCat cells
(negative control cell line) were purchased from China
Center for Type Culture Collection (Wuhan University).
DMEM cell culture containing 10 % fetal calf serum was
cultivated using routine method. TRNzol total RNA ex-
traction kit and cDNA first chain synthesis kit were
bought from Tiangen Biotechnology (Beijing) Company
Limited. The primers of MY09/11 (CGTCCMARRGG
AWACTGATC, GCMCAGGGWCATAAYAATGG) and
the primers of human GAPDH (positive sense: AGAAGG
CTGGGGCTCATTTG, antisense: AGGGGCCATCCAC
AGTCTTC) were synthesized by Sangon Biotechnology
Company Limited (Shanghai). The mice anti-HPV1, 6, 11,
16, 18, 31 L1 multivalence monoclonal antibodies were
purchased from Millipore Corporation (MAB837). Rabbit
broad spectrum anti-HPV L1 multiclone purified antibody
[32] was produced by HangZhou HuaAn Biotechnology
Company Limited. Ф10nm colloidal gold labeled goat
anti-mice IgG was the product of Sigma Corporation
(G7652). Biotin-Antibiotin-Horseradish peroxidase
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bought from Wuhan Guge Biotechnology Company Lim-
ited. Mice antibody immunocytochemistry kit was the
product of Neo Bioscience Technology Company Limited.
Protein Marker was produced by Fermentas (SM0672).
Recombinant protein HPV18 L1 expressed by Sf9 in-
sect cells baculovirus expression system was a gift from
professor Xu Xue-mei who is working for the Institute
of Basic Medical Sciences, Chinese Academy of Med-
ical Sciences [33].
HeLa cells and HaCat cells total protein and mRNA
extraction
Total protein was extracted from HeLa cells and HaCat
cells by routine method of mono-decontaminate lysate.
Extracted protein was sub-packaged into a 0.5 ml centri-
fuge tube and was preserved at − 20 °C. The total mRNA
was extracted by TRNzol total RNA extraction kit pro-
cedure while the cells were cultivated and preserved
at − 70 °C.
HPV L1 protein expression assay by ELISA
Appropriate protein sample was transferred into 96 wells
ELISA plate, and was diluted with 0.05 M carbonate buf-
fer solution up to 15–20 μg/ml, then it was coated to
stay overnight at 4 °C. On the second day, the plate was
washed with phosphate buffer solution (PBS), and then
blocked by 3 % Bovine Serum Albumin (BSA). After
blocking solution was removed, mice HPV L1 antibody
was diluted by 1:5000 and added to the wells. Next, the
plate was washed with PBS, which was followed by
addition of 1:1000 diluted goat anti-mice IgG antibody
labeled by horse radish peroxidase and incubating at
37 °C for 1 h. After being washed with PBS and colored
by TMB chromogenic solution, the reaction was termi-
nated by adding 2 M H2SO4. Then, the optical density
values were read by 450 nm microplate reader and the
experiments were repeated in 3 replicates to get the
average value. The obtained optical density (OD) values
were calculated using the formula (sample OD value-
blank) divided by (negative-blank), so the calculated
value of ≥2.1 means that it is a positive reaction. Soft-
ware SPSS13 was used to get the average values x  Sð Þ
and to carry out single factor variance analysis in order
to calculate the P value.
Reverse transcription polymerase chain reaction
(RT-PCR) assay
The first chain cDNA was synthetized by the cDNA first
chain synthesis kit using HeLa cells total mRNA. PCR
amplification reaction was done using 10 % of the first
chain cDNA reaction liquid. Amplification primer used
was the HPV L1 universal primer MY09/11 and the
products were about 450 bp. PCR products wereprocessed by agarose gel electrophoresis and the pictures
were taken by gel imaging system. GAPDH was used as
a internal control. The products were 258 bp.
HPV L1 protein expression assay by light microscope
immunocytochemistry
Cell slides with fixed HeLa cells and HaCat cells were
put into a glass plate pool. It was washed with PBS
which was followed by addition of 3 % H2O2 to remove
endogenous peroxidase. After washing with PBS again,
anti-HPV 1, 6, 11, 16, 18, 31 L1 monoclonal antibody
(concentration 1:1500) was added to the cells and incu-
bated for 1 h. After another wash with PBS, biotinylation
goat anti-mice IgG second antibody is added to the system
which was following by a wash with PBS and addition of
Biotin-Antibiotin-Horseradish peroxidase compounds.
The system was then washed with PBS, stained by DAB
chromogenic solution, then washed with PBS and coun-
terstained with hematoxylin. Finally, the cell sample was
rinsed with water, then dehydrated, cleared, gum sealed
and examined by light microscopy.
HPV L1 protein expression assay by electron microscope
immunocytochemistry
Logarithmic phase growing HeLa cells were collected by
centrifugation after they were digested by 0.5 % trypsin.
The sedimentation was fixed by 1.0 % glutaraldehyde
and was made into ultrathin sections under transmission
electron microscope. The ultrathin sections were put in
the nickel network and etched with 10 % H2O2 for
10 min. After washed with PBS, 1:500 mice anti-HPV1, 6,
11, 16, 18, 31 L1 monoclonal antibody and 1:200 Ф10nm
gold colloid labeled goat anti-mice IgG were added to the
section. When the reaction reached completion, it was
counterstained by uranium and lead, followed by the
examination of the sample under Hitachi HT-7500 trans-
mission electron microscope.
HPV L1 protein expression assay by Western blotting
Ready-processed protein samples and recombinant HPV18
L1 protein were added into SDS-PAGE gel sample holes
for electrophoresis, and then the gel was protein trans-
ferred. After protein transfer, the NC membrane was
treated with 3 % BSA blocking buffer solution, then de-
tected by mice anti-HPV1, 6, 11, 16, 18, 31 L1 monoclo-
nal antibody. The mice monoclonal antibody was
diluted by TBS solution containing 5 % calf serum to
1:10000 and then was oscillated with NC membrane
for 2 h. After being washed with TBS, the hatched mem-
brane was oscillated with HRP labeled goat anti-mice
IgG diluted to 1:4000 by TBS (which contains 5 %
calf serum). The membrane washed by TBS was then
stained by DAB stain solution. Lastly, double distilled
water was used to terminate the reaction and the
Xiao et al. Cancer Cell International  (2015) 15:53 Page 9 of 9membrane was taken out to dry and take pictures. In
the meantime, rabbit anti-HPV L1 antibody was used to
do the same detection with the same procedure as mice
monoclonal antibody.
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